Zheng Guo | Pharmacology | Best Researcher Award

Posted on by Best Achievements

Prof. Zheng Guo | Pharmacology | Best Researcher Award

Prof. Zheng Guo, Second Hospital of Shanxi Medical University, China.

Prof. Zheng Guo πŸŽ“, a renowned anesthesiologist and cardiovascular researcher, holds an M.B. from Shanxi Medical College and a Ph.D. from the University of Leeds. He has served as President of Shanxi Medical University and currently leads its Anesthesiology Department. His research focuses on myocardial ischemia, pain, and the autonomic nervous system πŸ«€πŸ§ . With multiple NSFC grants and publications in top-tier journals, Prof. Guo is a trailblazer in medical science and an inspiration to future researchers πŸ”¬πŸ“š.

Profile

Scopus Profile

Orcid Profile

πŸŽ“ Early Academic Pursuits

Prof. Zheng Guo began his academic journey with an M.B. from Shanxi Medical College in Taiyuan, China (1978–1983), laying a strong foundation in clinical medicine. Driven by a passion for scientific inquiry, he pursued a Ph.D. at the University of Leeds, UK (1988–1991), where he conducted pioneering research under the mentorship of Professor C.S. Goodchild. His early exposure to both clinical and translational research positioned him for a career at the intersection of medicine and science.

πŸ₯ Professional Endeavors

Prof. Guo has had an illustrious career spanning decades at Shanxi Medical University. He served as President (2000–2009) and earlier as Acting President (1998–2000), steering academic growth and institutional reform. Since 1994, he has chaired the Departments of Anesthesiology at The Second Hospital of Shanxi Medical University and has been a Professor of Anesthesiology since 1997. His enduring commitment to teaching, leadership, and clinical excellence continues to inspire the next generation of medical professionals.

πŸ”¬ Contributions and Research Focus On PharmacologyΒ 

Prof. Guo’s research centers on critical physiological mechanisms underlying myocardial ischemia/reperfusion injury, diabetes, stress responses, and the autonomic and sensory nervous systems, especially in relation to pain. His studies have elucidated how neurogenic and neuropeptidergic pathways affect cardiac health, with implications for anesthetic practices and cardiovascular therapies.

🌍 Impact and Influence

Prof. Guo’s work has significantly influenced both basic and clinical sciences in cardiology and anesthesiology. Through his dual leadership in research and education, he has elevated the global reputation of Shanxi Medical University. His mentorship has shaped numerous clinicians and researchers, contributing to the academic growth of the field in China and abroad.

🧠 Research Skills

Prof. Guo possesses comprehensive expertise in experimental cardiovascular pharmacology, pain modeling, neurophysiological assays, and animal model validation. His command over complex research methodologies and interdisciplinary collaboration has enabled groundbreaking discoveries in pain and cardiac injury mechanisms.

πŸ… Awards and Honors

Throughout his career, Prof. Guo has been recognized for his excellence in research and education. Although specific honors are not listed here, his leadership roles and consistent funding from prestigious bodies like the National Natural Science Foundation of China (NSFC) stand as testaments to his scientific and professional distinction.

Publications Top Notes

πŸ“„ Comprehensive validation of a custom three-point bending system for standardized diabetic fracture models in rats
πŸ‘¨β€πŸ”¬ Guo Q., Wang W., Guo Z.
🧬 Journal of Orthopaedic Surgery and Research, 2025
πŸ”§πŸ€ Focus: Diabetic fracture models, biomechanics

πŸ§ͺ Morphine timing-dependent modulation of TRPV1 phosphorylation correlates with differential morphine effects on myocardial ischemia/reperfusion injury
πŸ§‘β€πŸ”¬ Wang X., Li X., Jiang B., Wang T., Guo Z.
πŸ’‰ European Journal of Pharmacology, 2024
❀️‍πŸ”₯πŸ’Š Focus: Morphine effects on heart injury and TRPV1 receptor modulation

πŸ’” Epidural administration of large dose of opioid ΞΌ receptor agonist may impair cardiac functions and myocardial viability via desensitizing transient receptor potential vanilloid 1
πŸ§ͺ Ma X., Guo Z., Li M., Wang T., Sun T.
πŸ«€ Toxicology and Applied Pharmacology, 2024
πŸ§ πŸ’” Focus: Cardiac effects of high-dose opioids and TRPV1 receptor desensitization

πŸ«€ Antagonism of N/OFQ attenuates externalization of Ξ²1-adrenergic receptor and ventricular arrhythmias in acute myocardial ischemia rat model
πŸ”¬ Han Y., Xiong C., Zhang L., Yang G., Guo Z.
πŸ’‰ European Journal of Pharmacology, 2022
⚑❀️ Focus: Arrhythmia prevention through N/OFQ antagonism

πŸ•’ Impact of timing of morphine treatment on infarct size in experimental animal model of acute myocardial ischemia and reperfusion
πŸ§‘β€πŸ”¬ Lei Y., Li X., Guo Z.
🫁 European Journal of Pharmacology, 2022
β±οΈπŸ«€ Focus: Morphine timing and myocardial infarct size

Lucas Villas BΓ΄as Hoelz | Medicinal Chemistry | Best Researcher Award

Posted on by Best Achievements

Prof. Dr. Lucas Villas BΓ΄as Hoelz | Medicinal Chemistry | Best Researcher Award

Prof. Dr. Lucas Villas BΓ΄as Hoelz, Instituto Federal do Rio de Janeiro, IFRJ, Brazil.

πŸ§ͺ Prof. Dr. Lucas Villas Boas Hoelz is a distinguished chemist and researcher specializing in medicinal chemistry, molecular modeling, and organic synthesis. He earned his Ph.D. in Chemistry from the Federal University of Rio de Janeiro (UFRJ) and is a professor at the Federal Institute of Rio de Janeiro (IFRJ). As the coordinator of the Computational Medicinal Chemistry Laboratory (LCQM), his research focuses on COVID-19, neglected diseases, AIDS, and cancer. His contributions have significantly advanced therapeutic drug discovery and molecular dynamics. πŸ†

Professional Profile

πŸŽ“ Early Academic Pursuits

Prof. Dr. Lucas Villas Boas Hoelz embarked on his academic journey with a strong foundation in Pharmacy at the Universidade Federal do Rio de Janeiro (UFRJ), graduating in 2004. He later pursued a Master’s degree (2007) and a Doctorate (2011) in Chemistry at UFRJ. His doctoral research focused on the theoretical study of beta1-adrenoceptor activation mediated by R-noradrenaline, under the supervision of Ricardo Bicca de Alencastro. He further expanded his expertise through postdoctoral studies at UFRJ and the Programa de PΓ³s-Graduação em CiΓͺncias Aplicadas a Produtos para a SaΓΊde (PPG-CAPS), solidifying his expertise in medicinal chemistry and computational modeling.

πŸ’Ό Professional Endeavors

Dr. Hoelz has held multiple roles in academia and research. He currently serves as a Professor at the Instituto Federal do Rio de Janeiro (IFRJ) and is the coordinator of the Computational Medicinal Chemistry Laboratory (LCQM) at Campus Pinheiral-IFRJ. His professional trajectory includes positions as a temporary professor, tutor, and research fellow at various institutions. He has also contributed to postgraduate education as a permanent faculty member and graduate program mentor.

πŸ”¬ Contributions and Research Focus On Medicinal Chemistry

Dr. Hoelz specializes in Medicinal Chemistry, Organic Synthesis, Molecular Modeling, and Molecular Dynamics of Biological Systems. His research primarily addresses COVID-19, neglected diseases, AIDS, and cancer, focusing on the computational and experimental design of bioactive compounds. His work integrates comparative protein modeling, protein dynamics, and synthesis of new therapeutic agents, significantly advancing drug discovery efforts.

🌍 Impact and Influence

Through his research and academic contributions, Dr. Hoelz has played a key role in developing novel drug candidates and therapeutic strategies. His investigations into molecular interactions and drug mechanisms have informed the development of treatment methodologies for major global health concerns. His work has influenced both the scientific community and pharmaceutical industry, fostering innovation in medicinal chemistry.

πŸ“š Academic Citations

Dr. Hoelz’s research has been widely recognized and cited in various peer-reviewed journals and academic conferences. His studies on molecular modeling, organic synthesis, and drug discovery have garnered substantial academic interest, reflecting the impact and relevance of his work in the field of medicinal chemistry.

πŸ… Awards and Honors

Dr. Hoelz has received multiple scholarships and fellowships from prestigious organizations, including the Coordination for the Improvement of Higher Education Personnel (CAPES) and the National Council for Scientific and Technological Development (CNPq). His work has been recognized for its contributions to medicinal chemistry, with awards highlighting his excellence in research and teaching.

πŸš€ Legacy and Future Contributions

With a distinguished career in computational medicinal chemistry, Dr. Hoelz continues to expand his contributions by mentoring the next generation of researchers, publishing influential studies, and advancing computational approaches in drug design. His leadership at the LCQM ensures ongoing research in biomedical innovation, shaping the future of medicinal chemistry and molecular dynamics.

Publications Top Notes

🦠 Antiviral Research

1️⃣ The clinically approved antiviral drug sofosbuvir inhibits Zika virus replication
πŸ“œ Scientific Reports 7 (1), 40920
πŸ“… 2017 | πŸ”’ 250 citations

2️⃣ Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivo
πŸ“œ PLoS Neglected Tropical Diseases 13 (1), e0007072
πŸ“… 2019 | πŸ”’ 113 citations

3️⃣ In vitro antiviral activity of the anti-HCV drugs daclatasvir and sofosbuvir against SARS-CoV-2
πŸ“œ Journal of Antimicrobial Chemotherapy 76 (7), 1874-1885
πŸ“… 2021 | πŸ”’ 110 citations

4️⃣ Beyond Members of the Flaviviridae Family, Sofosbuvir Also Inhibits Chikungunya Virus Replication
πŸ“œ Antimicrobial Agents and Chemotherapy 63 (2), 10.1128/aac.01389-18
πŸ“… 2019 | πŸ”’ 103 citations

🦟 Malaria & Parasitic Disease Research

5️⃣ Evaluation of 7-arylaminopyrazolo [1, 5-a] pyrimidines as anti-Plasmodium falciparum inhibitors
πŸ“œ European Journal of Medicinal Chemistry 126, 72-83
πŸ“… 2017 | πŸ”’ 77 citations

6️⃣ Plasmodium Falciparum Dihydroorotate Dehydrogenase: A Drug Target against Malaria
πŸ“œ Future Medicinal Chemistry 10 (15), 1853-1874
πŸ“… 2018 | πŸ”’ 55 citations

7️⃣ Comparative study between anti-P. falciparum activity of triazolopyrimidine, pyrazolopyrimidine, and quinoline derivatives
πŸ“œ European Journal of Medicinal Chemistry 209, 112941
πŸ“… 2021 | πŸ”’ 34 citations

πŸ§ͺ Medicinal & Pharmaceutical Chemistry

8️⃣ Pyrroles as privileged scaffolds in the search for new potential HIV inhibitors
πŸ“œ Pharmaceuticals 14 (9), 893
πŸ“… 2021 | πŸ”’ 54 citations

9️⃣ Receptor-dependent (RD) 3D-QSAR approach of benzylpiperidine inhibitors of human acetylcholinesterase
πŸ“œ European Journal of Medicinal Chemistry 46 (1), 39-51
πŸ“… 2011 | πŸ”’ 32 citations

πŸ”Ÿ New pyrazolopyrimidine derivatives as Leishmania amazonensis arginase inhibitors
πŸ“œ Bioorganic & Medicinal Chemistry 27 (14), 3061-3069
πŸ“… 2019 | πŸ”’ 22 citations

🦠 Other Infectious Disease Research

1️⃣1️⃣ Structural and Functional Analysis of a Platelet-Activating Lysophosphatidylcholine of Trypanosoma cruzi
πŸ“œ PLoS Neglected Tropical Diseases 8 (8), e3077
πŸ“… 2014 | πŸ”’ 36 citations

1️⃣2️⃣ New 1,2,3‐triazole‐based analogues of benznidazole for use against Trypanosoma cruzi infection
πŸ“œ Medicinal Chemistry Research
πŸ“… Year N/A | πŸ”’ Citations N/A

πŸ”¬ Computational & Molecular Research

1️⃣3️⃣ Molecular dynamics simulations of the free and inhibitor-bound cruzain systems in aqueous solvent
πŸ“œ Journal of Biomolecular Structure and Dynamics 34 (9), 1969-1978
πŸ“… 2016 | πŸ”’ 20 citations

1️⃣4️⃣ P2X7 receptor inhibition by 2-amino-3-aryl-1,4-naphthoquinones
πŸ“œ Bioorganic Chemistry 104, 104278
πŸ“… 2020 | πŸ”’ 18 citations

πŸ₯ Cancer & Leukemia Research

1️⃣5️⃣ Imatinib derivatives as inhibitors of K562 cells in chronic myeloid leukemia
πŸ“œ Medicinal Chemistry Research 26, 2929-2941
πŸ“… 2017 | πŸ”’ 17 citations

πŸ—οΈ Green Chemistry & Synthesis

1️⃣6️⃣ Solvent Free, Microwave Assisted Conversion of Aldehydes into Nitriles and Oximes
πŸ“œ Molecules 15 (1), 94-99
πŸ“… 2009 | πŸ”’ 17 citations